Digital Therapeutics for Diabetes Market Size
The digital therapeutics for diabetes market reached US$ 12.84 billion in 2025 and is expected to reach US$ 58.81billion by 2035, growing at a CAGR of 17.23% during the forecast period 2026-203.
Digital therapeutics for diabetes refers to a category of evidence-based, software-driven solutions designed to prevent, manage or treat diabetes, leveraging digital technology, behavioral science and personalized data. These solutions are intended to be used either as stand-alone therapies or in conjunction with traditional treatments such as medications and insulin. They aim to help patients manage their condition by addressing the root causes of diabetes, such as lifestyle factors, medication adherence and glucose regulation, through real-time monitoring, behavior modification and patient education.
The demand for digital therapeutics for diabetes is experiencing significant growth, driven by the increasing prevalence of diabetes and the need for continuous disease management. This growth is primarily fueled by the rising adoption of smartphones and digital health technologies, which provide cost-effective, scalable and personalized management solutions for chronic diseases like diabetes. For instance, according to the Peterson Health Technology Institute (PHTI), the economic impact on purchasers of digital diabetes management solutions depends on the price of the digital solution and how it affects patterns of healthcare utilization and spending for patients who use them. It assumes a 25% adoption rate among eligible users.
Digital Therapeutics for Diabetes Market Key Takeaways
- The Digital Therapeutics for Diabetes Market was valued at US$ 12.84 billion in 2025 and is projected to reach US$ 58.81 billion by 2035, growing at a CAGR of 17.23%.
- Software solutions dominate the market due to widespread adoption of mobile health applications, AI-driven platforms, and connected diabetes management tools.
- The increasing global prevalence of Type 1 and Type 2 diabetes is driving demand for personalized, remote disease management solutions.
- North America leads the market, supported by advanced healthcare infrastructure, high digital health adoption, and strong technology penetration.
- Asia-Pacific is the fastest-growing region, fueled by expanding internet access, smartphone usage, and government-led digital healthcare initiatives.
- Strategic collaborations between digital therapeutics providers, pharmaceutical companies, and healthcare organizations are accelerating innovation and integrated diabetes care.
- Data privacy, cybersecurity, and regulatory compliance remain key challenges influencing market adoption and vendor selection.
Digital Therapeutics for Diabetes Market Market Scope
| Metrics | Details |
| Market Size (2025) | US$ 12.84 Billion |
| Market Size (2035) | US$ 58.81 Billion |
| CAGR (2026-2035) | 17.23% |
| Historic Years | 2023-2024 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Revenue Unit | US$ Billion |
| Segments Covered | Product Type, Application, End User, Region |
| Leading Region | North America |
| Fastest Growing Region | Asia-Pacific |
Executive Summary
For more details on this report – Request for Sample
Digital Therapeutics for Diabetes Market Dynamics: Drivers & Restraints
Rising prevalence of diabetes
The rising prevalence of diabetes is significantly driving the growth of the digital therapeutics for diabetes market and is expected to drive the market over the forecast period, as the increasing number of people diagnosed with diabetes necessitates new, scalable and effective treatment options. Digital therapeutics are seen as an efficient way to manage diabetes, especially with the growing demand for remote care, personalized treatment plans and real-time monitoring.
For instance, according to the International Diabetes Federation, in 2021, 536.6 million adults (20-79 years) are living with diabetes i.e., 1 in 10 people. This number is predicted to rise to 642.8 million by 2030 and 783.7 million by 2045. Over 3 in 4 adults with diabetes live in low- and middle-income countries. Diabetes is responsible for 6.7 million deaths in 2021 - 1 every 5 seconds. 541 million adults have Impaired Glucose Tolerance (IGT), which places them at high risk of type 2 diabetes. This escalating prevalence highlights the urgent need for accessible and cost-effective diabetes management solutions.
Diabetes is a chronic condition requiring lifelong management and digital therapeutics provide a means to continuously monitor and adjust treatment plans. Digital platforms and connected devices, like continuous glucose monitors (CGMs), mobile apps, and insulin dose trackers, offer real-time data, allowing for more personalized care. This is particularly useful for the Type 1 and Type 2 diabetes populations, where adherence to treatment plans is crucial.
For instance, BlueStar (powered by Welldoc), a digital therapeutic solution for diabetes management, integrates with insulin dosing recommendations and continuous glucose monitoring to provide personalized guidance, demonstrating the growing importance of digital therapeutics in day-to-day diabetes management.
Data privacy concerns
Data privacy concerns are a significant barrier to the growth of digital therapeutics for the diabetes market, as they directly impact trust, adoption rates and regulatory compliance. Digital therapeutics involve the collection and processing of sensitive health data, such as glucose levels, insulin doses and lifestyle habits, which raises concerns regarding the security, storage and sharing of this information.
Digital health platforms for diabetes management often require users to input personal health information, including real-time data from devices like continuous glucose monitors (CGMs) or smart insulin pens. This data, being highly sensitive, must be handled with the utmost care to avoid breaches that could expose personal health information.
For instance, according to the HIPAA Journal, in August 2023, 23 million breached healthcare records are noticed. Over the past 12 months, an average of 9,989,003 healthcare records were breached each month. In the year to August 31, 2024, there have been 491 data breaches of 500 or more records, and at least 58,668,002 records are known to have been breached. The average breach size in 2024 is currently 119,487 records and the median breach size is 4,109 records.
Digital Therapeutics for Diabetes Market Segment Analysis
The global digital therapeutics for diabetes market is segmented based on product type, application, end-user and region.
Product Type:
The software solutions segment is expected to dominate the digital therapeutics for diabetes market share
The software segment grew from US$ 2.01 billion in 2022 to US$ 2.29 billion in 2023, owing to rising adoption in the global market.
The software solutions segment is expected to dominate the global digital therapeutics for diabetes market. Software-based solutions such as mobile apps and digital platforms allow patients to track glucose levels, insulin use, diet and physical activity, providing personalized feedback and treatment recommendations. Top of FormFor instance, in November 2024, PureHealth revealed a huge surge in users of Pura, the group’s AI-enabled app. With over 140,000 downloads to date, Pura aims to improve quality of life and lifespans by providing individuals with personalized data, empowering them to improve their health through user-friendly tools and tailored insights.
Mobile and web-based applications are easy to use and accessible for a wide range of patients, including those in rural or underserved areas. The growing smartphone penetration is a key factor in this segment’s dominance. For instance, in November 2023, Abbott launched its digital health tool, FreeStyle LibreLink app in India. The mobile app allows people who use the FreeStyle Libre system to measure their glucose readings on their mobile phones without pricking. The mobile app is compatible with iPhone and Android smartphones.
The integration of digital therapeutics software with wearable devices like continuous glucose monitors and smart insulin pens allows for seamless, continuous monitoring of diabetes. These integrations are essential for patients with Type 1 and Type 2 diabetes, who need real-time adjustments to their insulin and lifestyle. As mentioned above, Abbott's Freestyle Libre, connects with mobile apps to provide real-time glucose tracking, demonstrating the growing adoption of software solutions in diabetes management.
Digital Therapeutics for Diabetes Market Regional Analysis
The Digital Therapeutics for Diabetes Market demonstrates varying adoption patterns across regions, influenced by diabetes prevalence, healthcare infrastructure, digital health maturity, government initiatives, and technology accessibility. While North America continues to lead the global market due to advanced healthcare systems and widespread adoption of digital health solutions, Asia-Pacific is projected to register the fastest growth through 2035, supported by expanding internet connectivity, rising smartphone penetration, and increasing investments in digital healthcare infrastructure.
North America Digital Therapeutics for Diabetes Market
Mature Digital Health Ecosystem Supports Market Leadership
North America is expected to maintain the largest share of the global Digital Therapeutics for Diabetes Market throughout the forecast period. According to the source data, the regional market increased from US$ 1.29 billion in 2022 to US$ 1.47 billion in 2023, reflecting strong adoption of digital diabetes management solutions.
The region benefits from one of the world's highest diabetes burdens alongside advanced healthcare infrastructure, creating favorable conditions for digital therapeutic adoption. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 29.7 million Americans were living with diagnosed diabetes in 2021, representing 8.9% of the U.S. population, while millions more remain at risk of developing the disease.
North America's strong digital infrastructure further strengthens market expansion. High smartphone ownership, widespread internet accessibility, cloud-based healthcare platforms, and increasing adoption of wearable medical devices enable seamless implementation of digital therapeutic solutions across hospitals, specialty clinics, and homecare settings.
The region also serves as a major innovation hub for digital therapeutics, supported by leading companies such as Welldoc, Omada Health, Teladoc Health, Glooko, and Twin Health. Continuous investments in artificial intelligence, remote patient monitoring, connected glucose monitoring systems, and integrated care platforms continue to reinforce North America's competitive advantage.
Growing collaborations between pharmaceutical companies and digital therapeutics providers, together with increasing emphasis on value-based healthcare and remote patient management, are expected to sustain regional market leadership over the coming decade.
Europe Digital Therapeutics for Diabetes Market
Expanding Digital Healthcare Initiatives Strengthen Market Growth
Europe represents a significant market for digital therapeutics, driven by increasing diabetes prevalence, aging populations, and continuous investments in digital healthcare transformation. Healthcare systems across the region are increasingly adopting remote patient monitoring and software-based chronic disease management solutions to improve long-term clinical outcomes while reducing healthcare costs.
The region's well-established healthcare infrastructure supports the integration of digital therapeutics into routine diabetes care. Growing acceptance of telemedicine, electronic health records, connected medical devices, and AI-supported clinical decision-making further enhances adoption across hospitals and specialty clinics.
European healthcare providers are placing greater emphasis on preventive care and personalized disease management, encouraging the use of digital platforms that improve medication adherence, lifestyle modification, and continuous glucose monitoring. As governments continue expanding digital health strategies, Europe is expected to remain an important revenue-generating region throughout the forecast period.
Asia-Pacific Digital Therapeutics for Diabetes Market
Fastest-Growing Region Driven by Digital Transformation
Asia-Pacific is projected to record the fastest growth in the global Digital Therapeutics for Diabetes Market through 2035. The region is witnessing rapid digital healthcare transformation supported by increasing smartphone penetration, expanding internet access, rising diabetes prevalence, and government initiatives promoting digital health services.
Countries including India, China, Australia, Japan, and South Korea are experiencing growing adoption of mobile healthcare applications and connected medical devices. According to the source data, India had more than 700 million active internet users as of December 2022, including approximately 425 million users in rural areas, creating an extensive foundation for mobile-based digital therapeutic solutions.
Government programs are also supporting digital healthcare expansion. China's Healthy China 2030 initiative continues to encourage adoption of digital health technologies for chronic disease management, while several Asia-Pacific countries are investing in telemedicine infrastructure and healthcare digitization.
The combination of a rapidly expanding diabetic population, improving healthcare accessibility, increasing digital literacy, and rising investments from technology companies positions Asia-Pacific as the most attractive region for future market expansion.
South America Digital Therapeutics for Diabetes Market
Digital Health Adoption Creates Emerging Growth Opportunities
South America is gradually expanding its adoption of digital therapeutics as healthcare providers increasingly embrace remote patient monitoring and digital disease management solutions. Rising diabetes prevalence and improving access to mobile technologies are encouraging healthcare organizations to incorporate software-based therapeutic platforms into chronic disease care.
The region is witnessing increased investment in digital healthcare infrastructure, supported by broader internet accessibility and expanding smartphone usage. Although adoption remains lower than in North America and Europe, digital therapeutics offer significant potential to improve diabetes management, particularly in underserved and geographically dispersed populations.
Growing awareness of preventive healthcare, combined with ongoing healthcare modernization initiatives, is expected to create favorable opportunities for market participants over the forecast period.
Middle East & Africa Digital Therapeutics for Diabetes Market
Healthcare Digitalization Supports Long-Term Market Potential
The Middle East & Africa region is expected to experience steady growth as governments continue investing in healthcare modernization and digital transformation initiatives. Rising diabetes prevalence, increasing healthcare expenditure, and expanding mobile connectivity are gradually supporting adoption of digital therapeutics across the region.
Healthcare providers are increasingly utilizing digital health platforms to improve access to diabetes care, particularly in remote communities where specialist services remain limited. Mobile-based disease management applications and remote monitoring technologies offer cost-effective solutions for improving patient engagement and long-term disease control.
Although challenges related to healthcare infrastructure, reimbursement, and digital literacy remain, continued investment in healthcare technology and growing awareness of chronic disease management are expected to support gradual market expansion through 2035.
Digital Therapeutics for Diabetes Market Opportunities
The next decade presents significant commercial opportunities for stakeholders across the diabetes care ecosystem as healthcare increasingly transitions toward software-enabled chronic disease management. Technology developers can capitalize on expanding demand for AI-powered digital therapeutics that combine predictive analytics, behavioral coaching, and connected medical devices into personalized care pathways.
Pharmaceutical companies have an opportunity to enhance treatment adherence and patient outcomes by integrating digital therapeutics with diabetes medications, creating connected therapy ecosystems that extend beyond drug prescriptions. Recent collaborations between digital therapeutics providers and pharmaceutical manufacturers demonstrate the industry's movement toward combined therapeutic solutions that support both medication management and lifestyle intervention.
Healthcare providers and hospitals can leverage digital therapeutics to improve care continuity, reduce unnecessary hospitalizations, and expand remote patient management programs. As reimbursement models increasingly reward improved patient outcomes rather than service volume, digital therapeutics are expected to become an important component of value-based diabetes care.
Emerging markets also offer considerable growth potential as expanding smartphone penetration, improving internet infrastructure, and government-backed digital health initiatives increase accessibility to mobile-based diabetes management solutions. Companies capable of delivering localized, scalable, and cost-effective digital therapeutic platforms are likely to benefit from rising healthcare digitization across Asia-Pacific, Latin America, and selected Middle Eastern markets.
Digital Therapeutics for Diabetes Market Major Players
The major global players in the digital therapeutics for diabetes market includeiHealth Labs Inc., Omada Health, Inc.,Virta Health Corp., Welldoc, Inc., Teladoc Health, Inc., DarioHealth Corp., Twin Health, Inc., Click Therapeutics, Inc., Lark Technologies, Inc., Noom, Inc., Glooko, Inc. and among others.
Digital Therapeutics for Diabetes Market Key Developments
July 2026: The U.S. FDA formally classified diabetes digital behavioral therapeutic devices as Class II medical devices, establishing special controls for prescription software designed to provide digital behavioral therapy for diabetes management.
June 2026: Dexcom became the first participant selected for the FDA's TEMPO Digital Health Devices Pilot, supporting its AI-powered glucose health program that combines glucose, nutrition, activity, sleep, and stress data to provide personalized diabetes-management insights.
May 2026: Development of AI-powered digital therapeutics continued expanding, with personalized glucose prediction and decision-support technologies being explored to improve early detection of adverse glycemic events and support individualized diabetes management.
April 2026: Digital therapeutics increasingly integrated continuous glucose monitoring, behavioral interventions, and personalized digital guidance, strengthening their role in supporting lifestyle modification and glycemic control alongside conventional diabetes treatments.
March 2026: The global digital therapeutics market continued benefiting from strong diabetes demand, with diabetes accounting for 30.1% of the global digital therapeutics market in 2025, making it the largest application segment.
Why Purchase the Report?
- Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
- Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
- Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
- Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
- Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
- Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
- Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
- Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
- Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
- Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
- Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
- Post-market Surveillance: Uses post-market data to enhance product safety and access.
- Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
The global digital therapeutics for diabetes market report delivers a detailed analysis with 62 key tables, more than 52 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2026
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.
Suggestions for Related Report
- Global Remote Monitoring Wearables Market
- Global Digital Therapeutics Market
- Global Digital Pills for Mental Health Market
For more medical device related reports, please click here
